Skip to content
AlternativeMed

SPECIALTY TOPICS · GUIDE

Classic Psychedelics: What the Term Covers

Content last updated . This page has not been medically reviewed.

Back to Psychedelic Therapy

What the term covers

"Classic psychedelics" is a pharmacology term, not a cultural one. [2] A 2016 pharmacology review reports a consensus that these drugs are agonists or partial agonists at brain serotonin 2A receptors. [3]

An "agonist" is a substance that switches a receptor on. A receptor is a docking point on a brain cell. The page Serotonin Receptors in Plain Language explains what this does and does not tell us.

The four named examples

Each example has a different origin, which is one reason the word "classic" should not be read as "natural" or "traditional".
SubstanceOrigin as described in sources
PsilocybinComes from certain types of mushrooms found on nearly every continent. [4]
DMTFound in the leaves of the Psychotria viridis bush, one of the two plants in the Amazonian brew ayahuasca. [6]
MescalineA naturally occurring alkaloid found in cacti, mainly peyote and cacti of the Echinopsis genus. [7]

DMT and ayahuasca are not the same thing: see DMT vs Ayahuasca.

What they are reported to do

NIDA reports that people using these drugs describe vivid visions or sensations, a changed sense of self, and feelings ranging from intense happiness and connection to fear, anxiety and confusion. [2] NIDA says studies suggest the most prominent effects stem from activity in the prefrontal cortex and that these drugs temporarily disrupt communication between brain regions, including the default mode network. [2] How much that matters for any health benefit is a separate question, covered in Proposed Mechanisms vs Proven Clinical Outcomes.

What "classic" does not mean

  • Not "safe". NIDA says effects vary widely and can include fear, anxiety and dangerous behavior, and that there is some evidence these drugs might trigger a schizophrenia-like illness in people with predisposing factors. [2]
  • Not "the same drug". The four examples differ in origin, chemistry and the research behind them. See Why Different Substances Cannot Be Treated as Equivalent.

Evidence labels on this page

This page makes classification statements, not treatment claims. Where it touches approval it uses the label approved medicine (a regulator has approved a product for a stated use) only for what the regulator has actually approved. Treatment evidence for specific conditions is on the pages for major depressive disorder and PTSD. The full list of labels is in how we label evidence.

Education only

This guide describes categories. It gives no amounts, no sourcing or preparation information and no advice to use or to treat yourself.

Frequently asked questions

Are classic psychedelics all natural?

No. [4][7][5]

Do classic psychedelics all act only on 5-HT2A receptors?

No. Mescaline, for example, is reported to act at 5-HT2A and 5-HT2C receptors and also at noradrenaline and dopamine receptors, and DMT is described as a 5-HT1A/2A partial agonist. [7][6]

Are classic psychedelics approved to treat anything?

According to NIDA's page read 2026-10-22, no classic psychedelic is FDA approved for therapeutic use; two psilocybin formulations have Breakthrough Therapy designation for study in depression. [8]

More details: evidence, limits and cautions

The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.

Safety note
Fear and anxiety are among the most common difficult effects, and fatal overdoses are described by NIDA as rarely associated with typical use of the commonly used members of this group. [2] NIDA also says that illicitly made drugs can be contaminated with other dangerous substances. [2] For the full risk picture see Psychedelic Adverse Effects and Contraindications. In the US, 911 is the emergency number and 988 reaches the Suicide and Crisis Lifeline.
References
  1. US Food and Drug Administration, Psychedelic Drugs: Considerations for Clinical Investigations, Guidance for Industry (July 2026). Read 2026-10-22.
  2. National Institute on Drug Abuse, Psychedelic and Dissociative Drugs. Read 2026-10-22.
  3. Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264-355. Read 2026-10-22 (abstract on PubMed).
  4. National Institute on Drug Abuse, Psilocybin (Magic Mushrooms). Read 2026-10-22.
  5. Dos Santos RG, Hallak JEC. Ayahuasca: pharmacology, safety, and therapeutic effects. CNS Spectr. 2024;30(1):e2. Read 2026-10-22 (abstract on PubMed).
  6. Vamvakopoulou IA et al. Mescaline: The forgotten psychedelic. Neuropharmacology. 2023;222:109294. Read 2026-10-22 (abstract on PubMed).
  7. National Institute on Drug Abuse, Psychedelic and Dissociative Drugs as Medicines. Read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.